Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 04/26 10:01:09 pm
36.85 USD   +0.46%
04/26Sangamo raises $200M in follow-on
AQ
04/26PFIZER : Hosts Annual Meeting of Shareholders
BU
04/26Overshadowed by Takeda bid, Shire reports solid start to year
RE
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer : Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) - Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 07:16pm CEST

TIME: 8 a.m.

EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) holds a meeting of the Arthritis Advisory Committee to discuss supplemental new drug applications 203214 supplement 17, for XELJANZ (tofacitinib) tablets and 208246 supplement 3, for XELJANZ XR (tofacitinib) extended release tablets submitted by Pfizer Inc., for the treatment of adult patients with active psoriatic arthritis.

DATE: August 3, 2017

LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center, the Great Room, Room 1503, Silver Spring, Md.

CONTACT: Philip Bautista, 301-796-9001, [email protected]

(c) 2006 Federal Information & News Dispatch, Inc., source Washington Daybook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
04/26PFIZER : Trademark Application for "ADVIL PLUSTABS" Filed
AQ
04/26Sangamo raises $200M in follow-on
AQ
04/26PFIZER : Hosts Annual Meeting of Shareholders
BU
04/26Overshadowed by Takeda bid, Shire reports solid start to year
RE
04/26PFIZER INC. : quaterly earnings release
04/26PFIZER : FDA rejects Pfizers Herceptin biosimilar
AQ
04/26PFIZER : Pfizers Trumenba gets breakthrough status for meningococcal disease
AQ
04/26PFIZER : FDA panel affirms safety of Pfizer's Celebrex
AQ
04/26PFIZER : takes aim at UKs health tech industry
AQ
04/26PFIZER : Supporting Refugee Communities
PU
More news
News from SeekingAlpha
04/26VYM : Drop Has Given Me Pause 
04/26Pfizer declares $0.34 dividend 
04/26Opioid prescriptions dropped 12% in 2017 
04/25BIOGEN : Down Too Far, Too Fast? 
04/25FDA advisory committee backs cardiovascular safety data for Pfizer's Celebrex 
Financials ($)
Sales 2018 54 460 M
EBIT 2018 20 817 M
Net income 2018 12 632 M
Debt 2018 23 675 M
Yield 2018 3,74%
P/E ratio 2018 16,84
P/E ratio 2019 15,39
EV / Sales 2018 4,48x
EV / Sales 2019 4,26x
Capitalization 220 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 39,9 $
Spread / Average Target 8,9%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER2.32%220 455
JOHNSON & JOHNSON-9.68%338 522
NOVARTIS-8.69%202 567
ROCHE HOLDING LTD.-11.66%193 904
MERCK AND COMPANY5.97%161 967
AMGEN-1.13%114 902